Study of PALI-2108 for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 3 months, confirmed by a scope test and tissue sample.
- Your disease is moderate to severe, based on a scoring system that looks at symptoms like stool frequency, rectal bleeding, and the appearance of the colon during a scope.
- You have either had a poor response to, or couldn't tolerate, at least one previous ulcerative colitis treatment, OR you are currently on a stable dose of certain medications like steroids, immunosuppressants, or aminosalicylates.
- You do not have Crohn's disease, colitis limited to the rectum only, or a history of ischemic or radiation colitis.
- You have no recent or active suicidal thoughts or severe depression.
- You have not failed or been intolerant to more than 3 classes of advanced therapies (like biologics or JAK inhibitors) or more than 4 individual advanced therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
This study tests an investigational pill (PTT-621) for moderate to severe ulcerative colitis that hasn't responded well to standard treatments. It aims to see if the drug can reduce inflammation and improve symptoms, while checking safety and how the body handles it.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.